ǰÑÔ
ϵͳÐÔºì°ßÀÇ´¯(systemic lupus erythematosus,SLE)ÊÇÒ»ÖÖ×ÔÉíÃâÒ߽鵼µÄ£¬ÒÔÃâÒßÐÔÑ×֢Ϊͻ³öÌåÏֵģ¬ÀÛ¼°¶àϵͳ¡¢¶àÆ÷¹Ù¡¢¶à×éÖ¯Ë𺦵ÄÂýÐÔÈ«ÉíÐÔ¼²²¡¡£ÑªÇåÖб£´æÒÔ¿¹ºË¿¹Ìå¡¢¿¹dsDNA¿¹ÌåΪ´ú±íµÄ¶àÖÖ×ÔÉí¿¹Ìå¡£ÁÙ´²ÌåÏÖΪºã¾ÃµÍ¡¢Öжȷ¢ÈÈ£¬·¦Á¦¡¢ÌåÖØ¼õÇá£¬Ãæ¼Õ²¿µûÐκì°ß£¬ÊàŦÌÛÍ´£¬ÐİüÑ×£¬¼äÖÊÐÔ·ÎÑ×£¬ÀÇ´¯ÐÔÉöÑס¢Éñ¾ÏµÍ³¸Ä±äµÈÈ«ÉíÐÔÖ¢×´¡£»¯Ñé¼ì²éѪºìÂѰ×Ͻµ£¬°×ϸ°û»òѪС°åïÔÌ£¬»¼ÕßѪÇå¿É²éµ½¶àÖÖ¿¹ºË¿¹Ìå¡¢¿¹Á×Ö¬¿¹ÌåºÍ¿¹×é֯ϸ°û¿¹Ì塣ѪÇå×ܲ¹Ì庬ÃÍϽµ£¬ÓÈÆäÊÇC3º¬Á¿µÍÏÂÌåÏÖΪÔ˶¯ÆÚ¡£
SLEÊÇÒ»ÖÖ³£¼ûµÄÄÑÖÎÐÔ¼²²¡£¬ËäÈ»ÏÖÒÑÃ÷È·SLEÊÇÒ»ÖÖ×ÔÉíÃâÒß²¡£¬µ«È·Çв¡ÒòºÍ·¢²¡»úÖÆÉÐδÍêÈ«ÆÊÎö¡£Ò»Ñùƽ³£ÒÔΪÖ÷ÒªÓëÒÅ´«Óйأ¬ÇéÐÎÒòËØÊÇÒ»¸ö´ÎÒªÒòËØ¡£ÓÉÓÚSLE»¼ÕßÅ®ÐÔÏÔ×ŶàÓÚÄÐÐÔ(9:1),XȾɫÌå±àÂëµÄ»ùÒò¿ÉÄÜÓë´Ë²¡Óйء£ÕýÓÉÓÚÔÆÔÆ£¬ÔËÓÃÖÖÖÖ¶¯ÎïÄ£×Ó´Ó²î±ð½Ç¶È¶Ô̽ÌÖ±¾²¡µÄ·¢²¡»úÖÆ¡¢²¡Àíת±äºÍÖÎÁÆÒªÁì¾ßÓÐÖ÷ÒªÒâÒå¡£
SLE¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡¢×Ô¾õÐÔ¶¯ÎïÄ£×ӺͻùÒòÐÞÊζ¯ÎïÄ£×Ó3Àà¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
½µÖ²Íé(pristane)ÊÇÖеȳ¤¶ÈµÄÍéÁ´£¬Æä×÷ÓûúÖÆÓë×ô¼ÁÀàËÆ£¬¿ÉÒýÆðÑ×Ö¢ºÍÔöÇ¿ÃâÒß·´Ó¦¡£Ð¡Êó¸¹Ç»×¢Éä½µÖ²Íéºó£¬½µÖ²ÍéÓ͵α»µ¥ºËÍÌÊÉϸ°ûÍÌÊÉ£¬T¡¢BÁܰÍϸ°ûÔöֳȺ¼¯ÐγÉÈâÑ¿Öס£Tϸ°û¸ß¶È»î»¯£¬Bϸ°û·´Ó¦ÐÔÔö¸ß£¬±¬·¢¶àÖÖ×ÔÉí¿¹Ìå¡£ÒàÓÐÑо¿ÒÔΪ½µÖ²Íé¿Éͨ¹ýÏßÁ£ÌåËðÉË;¾¶ÓÕ·¢Ï¸°ûµòÍö£¬±¬·¢µÄºË¿¹ÔÆô¶¯ÁË×ÔÉíÃâÒß·´Ó¦¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
6¡«8ÖÜBALB/c´ÆÐÔСÊóÒ»´ÎÐÔ¸¹Ç»×¢Éä½µÖ²Íé0.5ml¡£×¢Éäǰ¼°×¢Éäºóÿ2ÖܽÓÄÉСÊóÍâÖÜѪ£¬¼ì²âѪÇåÖÐ×ÔÉí¿¹Ì壨¿¹dsDNA¡¢¿¹smRNPºÍ¿¹ºËÌÇÌåP0)¡£
¡¾Ä£×ÓÌØµã¡¿£º
½µÖ²Íé´¦Öóͷ£×éѪÇåÖÐ×ÜlgG¼°¿¹dsDNA¡¢¿¹ºËÌÇÌåP0¼°¿¹smRNP¿¹Ì庬Á¿´ÓµÚ2¸öÔÂÆð×îÏÈÒ»Á¬ÉÏÉý£¬×ÔµÚ3¸öÔÂÆð¿¹ºËÌÇÌåP0µÄ×ÔÉí¿¹ÌåµÄˮƽ¿ÉÏÔןßÓÚÒõÐÔ±ÈÕÕ×é¡£6¸öÔºó½µÖ²Íé´¦Öóͷ£×éСÊóÉöСÇòÖб£´æ´ó×ÚIgG³Á»ý£¬·ºÆðÖжȵ½ÖضȵÄÊàŦËðÉË£¬Á÷ʽϸ°ûÒǼì²â¸¹Ç»Ï¸°ûÖÐIFN-αÉøÍ¸Ï¸°ûÑÇȺµÄ±ÈÀý£¬½µÖ²Íé´¦Öóͷ£×éµÄϸ°ûÊý×îÏÔÖø¸ßÓÚÒõÐÔ±ÈÕÕ×é¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
´ËÄ£×Ó¿ÉÓÃÓÚSLE²¡Òò¡¢·¢²¡»úÖÆ¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÄÃâÒßµ÷Àí¡¢ÃâÒ߸´ºÏÎïÐÔÉöÑס¢ÖÎÁÆSLEÒ©ÎïµÄҩЧѧÑо¿µÈ¡£×¢ÖØ£º¢ÙËäÈ»ÓýµÖ²Íé¿ÉÔÚ²î±ð½ü½»ÏµÐ¡ÊóÓÕµ¼SLE£¬µ«¸÷Ʒϵ±¬·¢×ÔÉí¿¹ÌåµÄ¼¸Âʺ͵ζÈÓвî±ð£¬BALB/cByJ¡¢DBA/1¡¢C57BL/6J¾ù¿É±¬·¢¿¹Su¡¢¿¹RNP/Sm ¿¹Ì壨°Ð¿¹ÔÖ÷ҪΪU1RNP£©¡¢¿¹dsDNA¿¹Ìå¡¢¿¹ssDNA¿¹Ìå¡¢¿¹×éÂѰ׿¹Ì壬¶øA¡¢SW¡¢C57BL/6J¡¢SJL/JСÊó¿É±¬·¢¿¹ºËÌÇÌåP¿¹Ì壻¢Ú´ÆÐÔ½ÏÐÛÐÔÒ×ÓÕµ¼³öÀÇ´¯Ñù²¡±ä¡£
²Î¿¼ÎÄÏ×£º
1.¬ÁÕ£¬ÞÉ»ª¹ú£¬ÎâºñÉú£®»î»¯ÁܰÍϸ°û¼°ÆäȾɫÖÊÓÕµ¼¿¹ºË¿¹ÌåÌìÉú£®ÖлªÎ¢ÉúÎïѧºÍÃâÒßѧÔÓÖ¾£¬1999, 19(1):44-46
2.Àî½ðÖ¦£¬¶¡öÁ£¬Merim Boukherouba£¬µÈ£®PristaneÓÕµ¼Ð¡ÊóϵͳÐÔºì°àÀÇ´¯¶¯ÎïÄ£×ÓµÄÑо¿£®Ï¸°ûÓë·Ö×ÓÃâÒßѧÔÓÖ¾£¬2011,27(2): 119-122
3.ÂÞÑåÑ壬ÁÖÓÐÀ¤£¬»Æ´äÀö£¬µÈ£®¸Îϸ°ûÖÊÂѰ×ÓÕµ¼ÏµÍ³ÐÔºì°ßÀÇ´¯ÍÃÄ£×ÓµÄʵÑéÑо¿. ÃâÒßѧÔÓÖ¾£¬2011,27 (8):710-714
4.Bubier JA,Sproule TJ,Foreman O,el al. A critical role for TL-21 receptor signaling in the pathogenesis of systemic lupus erythemalosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A,2009, 106(5): 1518-1523
5.Chen J, Kubalak SW, Chien KR. Ventricular musclerestricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development, 1998, 125 (10): 1943-1949
6.Dubois EL,Horowitz RE,Demopoulos HB,et al. NZB/ NZW mice as a model of systemic lupus erythematosus£®JAMA, 1966, 195 (4):285-289
7.Han B,Moore PA, Wu J,et al. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosuslike synclrome. Arthritis Rheum, 2007,56 (11):3748-3758
8.Satoh M. Richards HB, Shaheen VM, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoanlibodies by pristane. Clin Exp lmmunol, 2000, 121(2):399-405
9.Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristine. J Exp Med, 1994, 180 (6):2341-2346
10.Takai T, Ono M, Hikida M, et al. Augmented humoral and anaphylaclic responses in Fc gamma R¢ò-deficienl mice. Nature, 1996,379(6563):346-349